105 related articles for article (PubMed ID: 36706843)
21. A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
Pattarawat P; Hunt JT; Poloway J; Archibald CJ; Wang HR
Cancer Chemother Pharmacol; 2021 Sep; 88(3):415-425. PubMed ID: 34043046
[TBL] [Abstract][Full Text] [Related]
22. Facile synthesis of near-infrared responsive on-demand oxygen releasing nanoplatform for precise MRI-guided theranostics of hypoxia-induced tumor chemoresistance and metastasis in triple negative breast cancer.
Zhang D; You Y; Xu Y; Cheng Q; Xiao Z; Chen T; Shi C; Luo L
J Nanobiotechnology; 2022 Mar; 20(1):104. PubMed ID: 35246149
[TBL] [Abstract][Full Text] [Related]
23. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
24. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
25. Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.
Valcourt DM; Dang MN; Scully MA; Day ES
ACS Nano; 2020 Mar; 14(3):3378-3388. PubMed ID: 32083466
[TBL] [Abstract][Full Text] [Related]
26. Potential Biomarker for Triple-Negative Breast Cancer Invasiveness by Optical Redox Imaging.
Feng M; Xu HN; Jiang J; Li LZ
Adv Exp Med Biol; 2021; 1269():247-251. PubMed ID: 33966225
[TBL] [Abstract][Full Text] [Related]
27. Molecular Engineering of an Organic NIR-II Fluorophore with Aggregation-Induced Emission Characteristics for In Vivo Imaging.
Wu W; Yang Y; Yang Y; Yang Y; Zhang K; Guo L; Ge H; Chen X; Liu J; Feng H
Small; 2019 May; 15(20):e1805549. PubMed ID: 30925013
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
[TBL] [Abstract][Full Text] [Related]
29. Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types.
Handgraaf HJM; Boonstra MC; Prevoo HAJM; Kuil J; Bordo MW; Boogerd LSF; Sibinga Mulder BG; Sier CFM; Vinkenburg-van Slooten ML; Valentijn ARPM; Burggraaf J; van de Velde CJH; Frangioni JV; Vahrmeijer AL
Oncotarget; 2017 Mar; 8(13):21054-21066. PubMed ID: 28416744
[TBL] [Abstract][Full Text] [Related]
30.
Song N; Zhao L; Zhu M; Zhao J
Contrast Media Mol Imaging; 2019; 2019():9502712. PubMed ID: 31598115
[TBL] [Abstract][Full Text] [Related]
31. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
32. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
33. Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy.
Sulaiman A; McGarry S; El-Sahli S; Li L; Chambers J; Phan A; Côté M; Cron GO; Alain T; Le Y; Lee SH; Liu S; Figeys D; Gadde S; Wang L
Mol Cancer Ther; 2019 Oct; 18(10):1755-1764. PubMed ID: 31308079
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis.
Humphries B; Wang Z; Oom AL; Fisher T; Tan D; Cui Y; Jiang Y; Yang C
Carcinogenesis; 2014 Oct; 35(10):2254-63. PubMed ID: 24925028
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
Wang S; Oh DY; Leventaki V; Drakos E; Zhang R; Sahin AA; Resetkova E; Edgerton ME; Wu W; Claret FX
Cancer Lett; 2019 Nov; 465():12-23. PubMed ID: 31473252
[TBL] [Abstract][Full Text] [Related]
36. Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133
Brugnoli F; Grassilli S; Lanuti P; Marchisio M; Al-Qassab Y; Vezzali F; Capitani S; Bertagnolo V
BMC Cancer; 2017 Sep; 17(1):617. PubMed ID: 28870198
[TBL] [Abstract][Full Text] [Related]
37. The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with
Bouchard A; Sikner H; Baverel V; Garnier AR; Monterrat M; Moreau M; Limagne E; Garrido C; Kohli E; Collin B; Bellaye PS
Cells; 2021 Dec; 10(12):. PubMed ID: 34943901
[TBL] [Abstract][Full Text] [Related]
38. Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery.
Tang C; Du Y; Liang Q; Cheng Z; Tian J
Mol Imaging Biol; 2020 Jun; 22(3):476-485. PubMed ID: 31228075
[TBL] [Abstract][Full Text] [Related]
39. In Vivo Isolation of a Highly-aggressive Variant of Triple-negative Human Breast Cancer MDA-MB-231 Using Serial Orthotopic Transplantation.
Yano S; Takehara K; Miwa S; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
Anticancer Res; 2016 Aug; 36(8):3817-20. PubMed ID: 27466482
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
